Evidence map›Paper›PMID 15561905›Full record

ReviewDiabetes2004

Five stages of evolving beta-cell dysfunction during progression to diabetes.

Gordon C Weir, Susan Bonner-Weir

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02502344 (The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance), which is not on this map. Cited by 490 papers.

0numbers the graph read from it
0cells of the map it votes in
490citing papers in PubMed
20.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02502344 phase4unknown statusstarted 2015, after this paper: background citation

The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance

Ran2015Enrolled60Registered outcomes1Posted comparisons0ConditionsInsulin ResistanceArmshealthy lifestyle, Metformin
PMID 18502303PMID 22385956PMID 25070616other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

490 citing papers in PubMed, 1,092 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

430 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gordon C WeirSection on Islet Transplantation and Cell Biology, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA. gordon.weir@joslin.harvard.edu
Susan Bonner-Weir
Joslin Diabetes Center · US

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
ISLET FUNCTION AND DIABETESR01DK035449 · NIDDK · JOSLIN DIABETES CENTER · PI WEIR, GORDON CAMPBELL · 1986 to 1999
–
NIDDK NIH HHS DK-35449NIDDK NIH HHS DK-36836
6 · The paper itself

Abstract

This article proposes five stages in the progression of diabetes, each of which is characterized by different changes in beta-cell mass, phenotype, and function. Stage 1 is compensation: insulin secretion increases to maintain normoglycemia in the face of insulin resistance and/or decreasing beta-cell mass. This stage is characterized by maintenance of differentiated function with intact acute glucose-stimulated insulin secretion (GSIS). Stage 2 occurs when glucose levels start to rise, reaching approximately 5.0-6.5 mmol/l; this is a stable state of beta-cell adaptation with loss of beta-cell mass and disruption of function as evidenced by diminished GSIS and beta-cell dedifferentiation. Stage 3 is a transient unstable period of early decompensation in which glucose levels rise relatively rapidly to the frank diabetes of stage 4, which is characterized as stable decompensation with more severe beta-cell dedifferentiation. Finally, stage 5 is characterized by severe decompensation representing a profound reduction in beta-cell mass with progression to ketosis. Movement across stages 1-4 can be in either direction. For example, individuals with treated type 2 diabetes can move from stage 4 to stage 1 or stage 2. For type 1 diabetes, as remission develops, progression from stage 4 to stage 2 is typically found. Delineation of these stages provides insight into the pathophysiology of both progression and remission of diabetes.

Indexed as

AnimalsCell DifferentiationDiabetes Mellitus, Type 2Disease ProgressionHumansInsulinInsulin SecretionIslets of LangerhansIslets of Langerhans TransplantationModels, BiologicalInsulin

Identifiers

PMID15561905
OpenAlexW2133222023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.